Erika Martinelli

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 212 publications

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies.

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies.

Journal: ESMO gastrointestinal oncology

Published: August 28, 2026

Correction: Radiomics of portal-phase ring enhancement: a novel imaging biomarker for bevacizumab response associated with overall survival rates. It might help with surgical decision-making in colorectal liver metastases?

Correction: Radiomics of portal-phase ring enhancement: a novel imaging biomarker for bevacizumab response associated with overall survival rates. It might help with surgical decision-making in colorectal liver metastases?

Journal: Updates in surgery

Published: August 07, 2026

HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study.

HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancer.

Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancer.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study.

Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study.

Journal: ESMO gastrointestinal oncology

Published: March 27, 2026

Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center's real-world approach.

Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center's real-world approach.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling.

Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling.

Journal: Nature reviews. Clinical oncology

Published: January 30, 2026

Radiomics of portal-phase ring enhancement: a novel imaging biomarker for bevacizumab response associated with overall survival rates. It might help with surgical decision-making in colorectal liver metastases?

Radiomics of portal-phase ring enhancement: a novel imaging biomarker for bevacizumab response associated with overall survival rates. It might help with surgical decision-making in colorectal liver metastases?

Journal: Updates in surgery

Published: November 07, 2025

Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial.

Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 04, 2025

Delta-Radiomics Biomarker in Colorectal Cancer Liver Metastases Treated with Cetuximab Plus Avelumab (CAVE Trial).

Delta-Radiomics Biomarker in Colorectal Cancer Liver Metastases Treated with Cetuximab Plus Avelumab (CAVE Trial).

Journal: Diagnostics (Basel, Switzerland)

Published: October 24, 2025

Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer patients: demystifying the 100% clinical complete response paradigm.

Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer patients: demystifying the 100% clinical complete response paradigm.

Journal: The oncologist

Published: October 02, 2025

Radiomics meets pathology: Building the bridge for precision oncology.

Radiomics meets pathology: Building the bridge for precision oncology.

Journal: CytoJournal

Published: September 22, 2025

Showing 1-12 of 212

Last Updated: 09/26/2026